XVIVO held a digital Capital Markets Day on September 21, 2022. At the event, the company presented its increasingly strong financial position and reinforced its strategy to become global leader in the transplant industry. Guest speaker Professor David McGiffin, the coordinating principal investigator of the ANZ NIHP clinical trial in Australia, also presented his experience with XVIVO’s new heart technology.
XVIVO’s Capital Markets Day was held on September 23, 2021 at GoCo Health Innovation City in Gothenburg. Dag Andersson, CEO and members of the XVIVO management team covered company strategy, objectives and took deep dives into key projects and innovative technologies.
The event also included sections with external guests, including Filip Rega, Professor Dr at University Hospitals Leuven and the principal investigator of XVIVOs European Heart preservation study, Brandi Zofkie, Director and Ex Vivo Lung Specialist at Lung Bioengineering and Muhammad M. Mohiuddin, Professor of Surgery and Director of the Cardiac Xenotransplantation program at University of Maryland School of Medicine. The Capital Markets Day was moderated by financial analyst and journalist, Lars Frick.